Enhancement of diagnostic performance in lung cancers by combining CEA and CA125 with autoantibodies detection

References

• Cheng TY, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The International Epidemiology of Lung Cancer: latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016;11(10):1653–1671. doi:10.1016/j.jtho.2016.05.021.
   PubMed Web of Science ®Google Scholar
• Aberle DR, Adams AM, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, et al., National Lung Screening Trial Research T. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409. doi:10.1056/NEJMoa1102873.
   PubMed Web of Science ®Google Scholar
• McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112(Suppl 1):S108–115. doi:10.1038/bjc.2015.49.
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. N Engl J Med. 2007;357(22):2277–2284. doi:10.1056/NEJMra072149.
   PubMed Web of Science ®Google Scholar
• Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes A-M, Aughenbaugh GL, Bungum AO, Allen KL. CT screening for lung cancer: five-year prospective experience. Radiology. 2005;235(1):259–265. doi:10.1148/radiol.2351041662.
   PubMed Web of Science ®Google Scholar
• Grunnet M, Sorensen JB. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 2012;76(2):138–143. doi:10.1016/j.lungcan.2011.11.012.
   PubMed Web of Science ®Google Scholar
• Salgia R, Harpole D, Herndon JE 2nd, Pisick E, Elias A, Skarin AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Res. 2001;21:1241–1246.
   PubMed Web of Science ®Google Scholar
• Cedres S, Nunez I, Longo M, Martinez P, Checa E, Torrejón D, Felip E. Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 2011;12(3):172–179. doi:10.1016/j.cllc.2011.03.019.
   PubMed Web of Science ®Google Scholar
• Tarro G, Perna A, Esposito C. Early diagnosis of lung cancer by detection of tumor liberated protein. J Cell Physiol. 2005;203(1):1–5. doi:10.1002/jcp.20195.
   PubMed Web of Science ®Google Scholar
• Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Müller-Lux A, Gross IM, Wiethege T, Weber A, et al. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos. Arch Toxicol. 2011;85(3):185–192. doi:10.1007/s00204-010-0580-2.
   PubMed Web of Science ®Google Scholar
• Pastor A, Menendez R, Cremades MJ, Pastor V, Llopis R, Aznar J. Diagnostic value of SCC, CEA and CYFRA 21.1 in lung cancer: a Bayesian analysis. Eur Respir J. 1997;10:603–609.
   PubMed Web of Science ®Google Scholar
• Zhong L, Coe SP, Stromberg AJ, Khattar NH, Jett JR, Hirschowitz EA. Profiling tumor-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2006;1:513–519.
   PubMed Web of Science ®Google Scholar
• Desmetz C, Mange A, Maudelonde T, Solassol J. Autoantibody signatures: progress and perspectives for early cancer detection. J Cell Mol Med. 2011;15(10):2013–2024. doi:10.1111/j.1582-4934.2011.01355.x.
   PubMed Web of Science ®Google Scholar
• Wang W, Zhong W, Chen C, Meng Q, Wei J. Circulating Antibodies to Linear Peptide Antigens Derived from ANXA1 and FOXP3 in Lung Cancer. Anticancer Res. 2017;37(6):3151–3155. doi:10.21873/anticanres.11673.
   PubMed Web of Science ®Google Scholar
• Wang W, Guan S, Sun S, Jin Y, Lee K-H, Chen Y, Wei J. Detection of circulating antibodies to linear peptide antigens derived from ANXA1 and DDX53 in lung cancer. Tumour Biol. 2014;35(5):4901–4905. doi:10.1007/s13277-014-1643-4.
   PubMedGoogle Scholar
• Fu QF, Liu Y, Fan Y, Hua S-N, Qu H-Y, Dong S-W, Li R-L, Zhao M-Y, Zhen Y, Yu X-L, et al. Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol. 2015;8:22. doi:10.1186/s13045-015-0117-5.
   PubMed Web of Science ®Google Scholar
• Shih NY, Lai HL, Chang GC, Lin H-C, Wu Y-C, Liu JM, Liu K-J, Tseng S-W. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients. Jpn J Clin Oncol. 2010;40(7):663–669. doi:10.1093/jjco/hyq028.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim YM, Lim S, Nam YK, Jeong J, Kim H-J, Lee K-J. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene. 2009;28(1):117–127. doi:10.1038/onc.2008.364.
   PubMed Web of Science ®Google Scholar
• Hibi K, Westra WH, Borges M, Goodman S, Sidransky D, Jen J. PGP9.5 as a candidate tumor marker for non-small-cell lung cancer. Am J Pathol. 1999;155(3):711–715. doi:10.1016/S0002-9440(10)65169-3.
   PubMed Web of Science ®Google Scholar
• Bittencourt Rosas SL, Caballero OL, Dong SM. da Costa Carvalho Mda G, Sidransky D, Jen J. Methylation status in the promoter region of the human PGP9.5 gene in cancer and normal tissues. Cancer Lett. 2001;170:73–79.
   PubMed Web of Science ®Google Scholar
• Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001;61:7908–7912.
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Nishikawa H, Jungbluth AA, Güre AO, Ritter G, Jäger E, Knuth A, Chen Y-T, Old LJ. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006;95:1–30. doi:10.1016/S0065-230X(06)95001-5.
   PubMed Web of Science ®Google Scholar
• Yang J, Jiao S, Kang J, Li R, Zhang G. Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis. Int J Clin Exp Pathol. 2015;8:14959–14964.
   PubMed Web of Science ®Google Scholar
• Wang J, Shivakumar S, Barker K, Tang Y, Wallstrom G, Park JG, Tsay J-CJ, Pass HI, Rom WN, LaBaer J, et al. Comparative Study of Autoantibody Responses between Lung Adenocarcinoma and Benign Pulmonary Nodules. J Thorac Oncol. 2016;11(3):334–345. doi:10.1016/j.jtho.2015.11.011.
   PubMed Web of Science ®Google Scholar
• Pereira-Faca SR, Kuick R, Puravs E, Zhang Q, Krasnoselsky AL, Phanstiel D, Qiu J, Misek DE, Hinderer R, Tammemagi M, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res. 2007;67(24):12000–12006. doi:10.1158/0008-5472.CAN-07-2913.
   PubMed Web of Science ®Google Scholar
• Chang YC, Chan YC, Chang WM, Lin Y-F, Yang C-J, Su C-Y, Huang M-S, Wu ATH, Hsiao M. Feedback regulation of ALDOA activates the HIF-1alpha/MMP9 axis to promote lung cancer progression. Cancer Lett. 2017;403:28–36. doi:10.1016/j.canlet.2017.06.001.
   PubMed Web of Science ®Google Scholar
• Falck Miniotis M, Arunan V, Eykyn TR, Marais R, Workman P, Leach MO, Beloueche-Babari M. MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res. 2013;73(13):4039–4049. doi:10.1158/0008-5472.CAN-12-1969.
   PubMed Web of Science ®Google Scholar
• Trivers GE, De Benedetti VM, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res. 1996;2:1767–1775.
   PubMed Web of Science ®Google Scholar
• Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Consortium for Early Detection of Lung Cancer, Guida F, Sun N, Bantis LE, Muller DC, Li P, et al. Assessment of Lung Cancer Risk on The Basis of a Biomarker Panel of Circulating Proteins. JAMA Oncol. 2018;4(10):e182078.
   Google Scholar
• Yang D, Zhang X, Powell CA, Ni J, Wang B, Zhang J, Zhang Y, Wang L, Xu Z, Zhang L, et al. Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study. Cancer. 2018;124(2):262–270. doi:10.1002/cncr.31020.
   PubMed Web of Science ®Google Scholar
• Qiu J, Choi G, Li L, Wang H, Pitteri SJ, Pereira-Faca SR, Krasnoselsky AL, Randolph TW, Omenn GS, Edelstein C, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008;26(31):5060–5066. doi:10.1200/JCO.2008.16.2388.
   PubMed Web of Science ®Google Scholar
• Ohue Y, Wada H, Oka M, Nakayama E. Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients. Oncoimmunology. 2014;3(11):e970032. doi:10.4161/21624011.2014.970032.
   PubMed Web of Science ®Google Scholar
• Chapman CJ, Murray A, McElveen JE, Sahin U, Luxemburger U, Türeci O, Wiewrodt R, Barnes AC, Robertson JF. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008;63(3):228–233. doi:10.1136/thx.2007.083592.
   PubMed Web of Science ®Google Scholar
• Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. Febs J. 2009;276(23):6880–6904. doi:10.1111/j.1742-4658.2009.07396.x.
   PubMed Web of Science ®Google Scholar
• Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011;22(2):383–389. doi:10.1093/annonc/mdq361.
   PubMed Web of Science ®Google Scholar
• Lam S, Boyle P, Healey GF, Maddison P, Peek L, Murray A, Chapman CJ, Allen J, Wood WC, Sewell HF, et al. EarlyCDT-Lung: an immunobiomarker test as an aid to early detection of lung cancer. Cancer Prev Res (Phila). 2011;4(7):1126–1134. doi:10.1158/1940-6207.CAPR-10-0328.
   PubMed Web of Science ®Google Scholar
• Jett JR, Peek LJ, Fredericks L, Jewell W, Pingleton WW, Robertson JF. Audit of the autoantibody test, EarlyCDT(R)-lung, in 1600 patients: an evaluation of its performance in routine clinical practice. Lung Cancer. 2014;83(1):51–55. doi:10.1016/j.lungcan.2013.10.008.
   PubMed Web of Science ®Google Scholar
• Shan Q, Lou X, Xiao T, Zhang J, Sun H, Gao Y, Cheng S, Wu L, Xu N, Liu S. A cancer/testis antigen microarray to screen autoantibody biomarkers of non-small cell lung cancer. Cancer Lett. 2013;328(1):160–167. doi:10.1016/j.canlet.2012.08.019.
   PubMed Web of Science ®Google Scholar
• Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005;4(4):1123–1133. doi:10.1021/pr0500814.
   PubMed Web of Science ®Google Scholar
• Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T, Zhao L, Huang S, Liu S, Cao G. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res. 2010;16(14):3760–3768. doi:10.1158/1078-0432.CCR-10-0193.
   PubMed Web of Science ®Google Scholar
• Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK, Tan EM. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12:136–143.
   PubMed Web of Science ®Google Scholar
• Sakao Y, Tomimitsu S, Takeda Y, Natsuaki M, Itoh T. Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. Eur J Cardiothorac Surg. 2004;25(4):520–522. doi:10.1016/j.ejcts.2004.01.029.
   PubMed Web of Science ®Google Scholar
• Buccheri G, Ferrigno D. Identifying patients at risk of early postoperative recurrence of lung cancer: a new use of the old CEA test. Ann Thorac Surg. 2003;75:973–980.
   PubMed Web of Science ®Google Scholar
• Doseeva V, Colpitts T, Gao G, Woodcock J, Knezevic V. Performance of a multiplexed dual analyte immunoassay for the early detection of non-small cell lung cancer. J Transl Med. 2015;13:55. doi:10.1186/s12967-015-0541-x.
   PubMed Web of Science ®Google Scholar
• Veluswamy RR, Ezer N, Mhango G, Goodman E, Bonomi M, Neugut AI, Swanson S, Powell CA, Beasley MB, Wisnivesky JP. Limited Resection Versus Lobectomy for Older Patients With Early-Stage Lung Cancer: impact of Histology. J Clin Oncol. 2015;33(30):3447–3453. doi:10.1200/JCO.2014.60.6624.
   PubMed Web of Science ®Google Scholar